NewAmsterdam Pharma Company N.V.

NasdaqGM NAMS

NewAmsterdam Pharma Company N.V. EPS (Diluted) for the year ending December 31, 2023: USD -2.15

NewAmsterdam Pharma Company N.V. EPS (Diluted) is USD -2.15 for the year ending December 31, 2023, a -93.69% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

NewAmsterdam Pharma Company N.V. EPS (Diluted) for the year ending December 31, 2022 was USD -1.11, a 66.77% change year over year.
NewAmsterdam Pharma Company N.V. EPS (Diluted) for the year ending December 31, 2021 was USD -3.34, a -190.43% change year over year.
NewAmsterdam Pharma Company N.V. EPS (Diluted) for the year ending December 31, 2020 was USD -1.15.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

NasdaqGM: NAMS

NewAmsterdam Pharma Company N.V.

CEO	Dr. Michael Harvey Davidson FACC, Facp., M.D.
IPO Date	Feb. 9, 2021
Location	Netherlands
Headquarters	Gooimeer 2-35
Employees	62
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

Key trends

Past 5 years